Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022. The court ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...

(Bloomberg) -- Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract. The Cambridge, Massachusetts-based ...

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past year, due to fading vaccine demand and pipeline uncertainty.

Moderna shares fell more than 5% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine.

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...

Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Friday, February 14th, before market open. Analysts expect a loss of $2.73 on revenue of $941.14M (-66.5% Y/Y). According to ...